What podcasts say about Lauren Martz
Every statement, with the speaker, the exact quote and the moment it was said.
What Lauren Martz has said on podcasts
24 statements · 13 positive · 7 negative · 2 mixed · 2 neutral
Pelacarsen showed no efficacy across tested trial subgroups.
“Pella-Carson really didn't show any efficacy at all against any of the subgroups that were tested in this trial.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 18:02
Pelacarsen reduced Lp(a) by approximately 80%.
“this was about 80%.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 19:07
Lp(a)-lowering therapy may work when used earlier or for primary prevention.
“this may work if you use it in a primary prevention setting or much earlier.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 19:21
Further large early-intervention Lp(a) trials are difficult to fund.
“who's going to fund an even bigger, even earlier study in the same mechanism? It's hard to envision that path forward.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 20:05
Lp(a) remains biologically plausible but lacks a clear development path.
“I'm not ready to give up on it, but I don't know that there is a drug development path forward for it.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 21:15
Late-stage Lp(a) therapies may produce similarly disappointing outcomes.
“it's hard to see a different outcome coming for the other, at least the other therapies that are in the late stage testing now.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 22:15
New solid-tumor immunotherapies target immunosuppression and systemic immune toxicity.
“they're trying to overcome two of the biggest challenges in cancer immunotherapy for solid tumors, which are the immunosuppressive tumor microenvironment and the systemic toxicities related to activating the immune system.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 23:04
Nonspecific CAR integration may cause secondary cancers.
“They don't integrate the car into a specific site in the DNA, which we know can be a problem. It can potentially cause secondary cancers, things like that.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 25:17
Site-specific CAR integration could become an important in vivo CAR-T approach.
“there are a few companies and academic groups now that are showcasing site-specific car integration for their in vivo car teas, which I think is something that could end up being very interesting.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 25:28
Argenx and Unnatural Products are pursuing an oral Vyvgart analogue.
“They're basically trying to create an oral Vivgart with unnatural.”
Open the episode · Ep. 397 - What the U.S. midterms mean for biopharmaListen at 27:00
ADCs outnumbered other modalities among ESMO first-in-human studies.
“antibody drug conjugates outnumbered any other modality in the set that we found”
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposalListen at 2:17
ADC payload innovation is lagging behind target innovation.
“the payload innovation is really lagging behind”
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposalListen at 3:21
ADC payloads are the primary resistance driver in breast cancer.
“the payload is actually the primary driver of resistance, at least in breast cancer”
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposalListen at 4:04
Changing ADC targets while retaining payload often produces little or no response.
“when you keep the payload consistent, but you change the tumor antigen that you're targeting in a patient who's already received an ADC against the same payload, different tumor antigen, there are almost no responses, zero responses in some cases”
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposalListen at 4:18
Switching ADC payloads can preserve responses during sequential therapy.
“if you switch up the payload, when you're doing sequential ADC therapies, you do continue to get some responses”
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposalListen at 4:34
ADC payload innovation should continue progressing.
“payload innovation needs to continue progressing”
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposalListen at 5:22
Most products in the first-in-human dataset had first-in-class potential.
“the majority of these products in first in human trials have first in class potential”
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposalListen at 6:50
Bispecific antibodies had a higher first-in-class proportion than ADCs.
“the bispecific antibodies, which had a... an even higher proportion of first-in-class potential products in this data set than the antibody drug conjugates”
Open the episode · Ep. 395 - ESMO analysis & Auchincloss proposalListen at 8:05
Pepstar’s oral IL-23 inhibitor lacked efficacy data and was in phase one testing.
“this is in, as I said, a phase one trial in healthy volunteers. We don't have any efficacy data”
Open the episode · Ep. 394 - Security concerns in U.S., China reshaping biotechListen at 20:06
Pepstar’s validated oral IL-23 mechanism could address a potentially large market.
“this is a potentially big market for something that's validated”
Open the episode · Ep. 394 - Security concerns in U.S., China reshaping biotechListen at 22:24
Merck and Moderna’s melanoma vaccine reduced recurrence-or-death risk by 42%.
“this personalized cancer vaccine for melanoma led to a 42% reduction in the risk of recurrence or death”
Open the episode · Ep. 394 - Security concerns in U.S., China reshaping biotechListen at 24:19
The personalized melanoma vaccine may require substantial clinical benefit for adoption.
“there might need to be a really meaningful clinical benefit for this to be adopted”
Open the episode · Ep. 394 - Security concerns in U.S., China reshaping biotechListen at 25:03
Renal-cell-carcinoma data for the vaccine strategy should arrive around early next year.
“around the beginning of next year should have some data from that program”
Open the episode · Ep. 394 - Security concerns in U.S., China reshaping biotechListen at 29:00
Amgen’s M-Delta results are highly impressive after moving into earlier-line treatment.
“the results that we're seeing as this by specific in particular has been moved to an earlier line of treatment are incredibly impressive”
Open the episode · Ep. 394 - Security concerns in U.S., China reshaping biotechListen at 32:09
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.